This test is most useful if any of these apply to you.
Hives that keep returning without an obvious trigger can involve antibodies that target your own immune proteins. Anti-IgE IgG is one candidate. It has been found in people with chronic hives and in healthy people, so detecting it doesn't establish why you're itching.
This is a clinically available marker whose interpretation remains exploratory. Research supports a role for some of these antibodies in hives, but the amount detected hasn't been validated as a stand-alone diagnosis, a measure of disease severity, or a way to choose treatment. There is no universally accepted diagnostic threshold or treatment target.
IgE is an antibody involved in immediate allergic reactions. It attaches to mast cells in tissues and basophils in blood. These immune cells can release histamine, which causes itching, swelling, and welts. An allergen can trigger that release by linking neighboring IgE molecules on a cell's surface.
IgG is another class of antibody. Some IgG antibodies bind to IgE itself and can link IgE molecules on cells without an outside allergen. Whether this happens depends on where and how the antibody binds. Antibodies that bind IgE can also have little effect or inhibit allergic cell activation.
This test detects IgG binding to IgE in serum from a blood draw. Serum is the liquid remaining after blood clots. The ELISA method exposes your sample to IgE attached to a plate and detects IgG that binds to it. It measures antibody binding; determining whether those antibodies activate cells requires a separate functional experiment.
Chronic spontaneous urticaria causes recurring hives, swelling, or both for more than six weeks without a consistent external trigger. Cold urticaria is different: cold exposure brings on the symptoms.
An early serum study found IgG anti-IgE in 5 of 9 people with cold urticaria. It also found the antibody in 3 of 6 people with chronic urticaria and 4 of 8 with urticarial vasculitis. Urticarial vasculitis causes hive-like lesions through inflammation of small blood vessels. These were very small groups, so the findings don't establish that half of everyone with chronic hives has this antibody.
Several positive serum samples made healthy donor basophils release histamine in laboratory experiments and produced a welt when injected into skin. One sample from someone with cold urticaria temporarily transferred cold sensitivity to another person's skin. Those experiments support a possible disease-causing role for certain antibodies.
Later research included 134 people with chronic spontaneous urticaria and 55 healthy controls in Japan. Anti-IgE IgG concentrations differed between the groups, and antibodies from the hives group had greater ability to link IgE receptors in a laboratory assay. The study supports the mechanism, but its research measurements do not establish how accurately this clinical test identifies the cause of an individual's hives.
Systemic sclerosis is a form of scleroderma that can thicken the skin and damage internal organs. In a study of 66 people with systemic sclerosis, about one in five had serum IgG anti-IgE. Samples with strong antibody signals failed to trigger basophil histamine release in laboratory experiments. The researchers found no association with disease extent, organ involvement, or mortality. This small study doesn't support using the antibody to diagnose scleroderma or forecast its course.
A study comparing 66 people with asthma with 20 healthy people without allergies found higher serum IgG1 and IgG4 anti-IgE levels in the asthma group. These are individual IgG subclasses, so the findings aren't directly interchangeable with this test's combined IgG measurement. Neither subclass tracked asthma severity.
A later study of combined IgG anti-IgE detected the antibodies in people with allergic asthma, people with non-allergic asthma, and healthy controls. Experiments with human basophils showed that some samples activated the cells while others inhibited their response to allergens. These laboratory findings help explain why a binding result alone doesn't reveal the antibody's effect in your body.
FcεRI is the receptor that holds IgE on mast cells and basophils. IgG antibodies can target this receptor instead of IgE itself. The two antibody tests measure different targets, even though both have been studied in autoimmune hives. Receptor antibodies are reported in roughly 30% to 50% of people with chronic hives, while antibodies against IgE itself are found in only about 5% to 10%. A positive result here is less common than many people expect, and a negative one is the usual finding.
A small study followed 20 people with chronic spontaneous urticaria during omalizumab treatment: 11 responded early, 7 responded late, and 2 didn't respond. Late responders had higher IgE and IgG antibodies against tissue factor, a clotting protein, and IgE and IgG autoantibodies tended to occur together in that group. Twenty people is far too few to turn this into a reliable treatment prediction for your result.
Research on Crohn's disease is mixed. One recent study found that serum IgG anti-IgE did not distinguish people with the disease from healthy controls, while antibodies against FcεRI did. An older study found higher levels of IgE bound together with anti-IgE in Crohn's serum than in healthy controls. These findings don't establish either antibody as a routine diagnostic test for Crohn's disease.
Research classification of type IIb autoimmune hives combines IgG against IgE or its receptor with evidence that serum activates basophils and produces a reaction in an autologous serum skin test. That skin test uses a small amount of your own serum. Antibody binding alone meets only one part of this research definition. In one large study of chronic spontaneous urticaria, 58% of people had a positive antibody immunoassay, but only 8% met all three criteria.
People meeting these combined criteria have tended to have lower total IgE, higher thyroid peroxidase antibodies, and lower basophil and eosinophil counts. Those are related findings from different tests. They can support an autoimmune explanation, but none proves that your anti-IgE IgG is causing symptoms.
Anti-IgE Antibody IgG is best interpreted alongside these tests.